Indocyanine Green Lymphography in Management of Lingual Lymphatic Malformation

Application Value of Indocyanine Green Lymphography in Management of Microcystic Lymphatic Malformation of the Tongue

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06755905

Enrollment

Registered

2025-01-01

Start date

2019-01-01

Completion date

2024-12-15

Last updated

2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphatic Malformation

Keywords

indocyanine green, tongue, Lymphatic Malformation

Brief summary

To elucidate the application of indocyanine green (ICG) fluorescence angiography in the treatment of childhood tongue cLM (clinically localized malignancy, presumed context here), providing a clearer scientific basis for subsequent targeted interventions.

Interventions

PROCEDUREICGL-guided treatment

Indocyanine green lymphography guided resection combined with sclerotherapy

PROCEDUREConventional Treatment group

Resection with sclerotherapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

No minimum to 14 Years

Healthy volunteers

Inclusion criteria

* No previous intervention * more than 6 months post-treatment follow-up * Stage I or Stage IIa

Exclusion criteria

* History of iodine allergy * Syndromic cLM * Severe liver and kidney dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Cured (Reduction in dimension greater than 90%)	From enrollment to the end of treatment at 12 weeks	Reduction in dimension greater than 90%

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026